RUBINSTEIN JULIE 4

4 · Adaptive Biotechnologies Corp · Filed Mar 5, 2026

Insider Transaction Report

Form 4

Period: 2026-03-03

Adaptive Biotechnologies CorpADPT

RUBINSTEIN JULIE

President and COO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-03$6.55/sh+14,722$96,429→ 602,971 total
Exercise/Conversion
Common Stock
[F1]
2026-03-03$12.14/sh+11,881$144,235→ 614,852 total
Sale
Common Stock
[F1][F2]
2026-03-03$15.49/sh−24,423$378,312→ 590,429 total
Sale
Common Stock
[F1][F3]
2026-03-03$16.33/sh−6,518$106,439→ 583,911 total
Exercise/Conversion
Common Stock
[F1]
2026-03-04$6.55/sh+14,722$96,429→ 598,633 total
Exercise/Conversion
Common Stock
[F1]
2026-03-04$12.14/sh+11,881$144,235→ 610,514 total
Sale
Common Stock
[F1][F4]
2026-03-04$16.60/sh−30,941$513,621→ 579,573 total
Exercise/Conversion
Common Stock
[F1]
2026-03-05$6.55/sh+14,722$96,429→ 594,295 total
Exercise/Conversion
Common Stock
[F1]
2026-03-05$12.14/sh+11,881$144,235→ 606,176 total
Sale
Common Stock
[F1][F5]
2026-03-05$16.00/sh−30,941$495,056→ 575,235 total
Exercise/Conversion
Stock Option (right to buy)
[F1][F6]
2026-03-03−14,722→ 180,603 total
Exercise: $6.55Exp: 2028-02-07→ Common Stock (14,722 underlying)
Exercise/Conversion
Stock Option (right to buy)
[F1][F7]
2026-03-03−11,881→ 451,463 total
Exercise: $12.14Exp: 2032-03-04→ Common Stock (11,881 underlying)
Exercise/Conversion
Stock Option (right to buy)
[F1][F6]
2026-03-04−14,722→ 165,881 total
Exercise: $6.55Exp: 2028-02-07→ Common Stock (14,722 underlying)
Exercise/Conversion
Stock Option (right to buy)
[F1][F6]
2026-03-04−11,881→ 439,582 total
Exercise: $12.14Exp: 2032-03-04→ Common Stock (11,881 underlying)
Exercise/Conversion
Stock Option (right to buy)
[F1][F6]
2026-03-05−14,722→ 151,159 total
Exercise: $6.55Exp: 2028-02-07→ Common Stock (14,722 underlying)
Exercise/Conversion
Stock Option (right to buy)
[F1][F6]
2026-03-05−11,881→ 427,701 total
Exercise: $12.14Exp: 2032-03-04→ Common Stock (11,881 underlying)

Footnotes (7)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
[F2]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
[F3]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
[F4]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $16.94, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
[F5]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $16.30, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
[F6]The option is fully vested and exercisable.
[F7]The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Signature

/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact|2026-03-05

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT